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Abstract Nanoparticle albumin-bound paclitaxel (nab-
paclitaxel) has demonstrated clinical benefit in metastatic
breast cancer (MBC) in a randomized phase III trial versus
paclitaxel (CA012; N = 454) and in a randomized phase II
trial versus docetaxel (CA024; N = 300). This retrospec-
tive analysis examines whether patients with poor prog-
nostic factors demonstrate similar outcomes to the intent-
to-treat (ITT) populations in these trials. This retrospective
analysis evaluated the efficacy and safety of previously
untreated patients with MBC with the following poor
prognostic factors: visceral dominant metastases and short
disease-free interval (DFI; B2 years). In CA012 (n = 186
first-line patients), nab-paclitaxel demonstrated a signifi-
cantly higher overall response rate (ORR) versus paclitaxel
in patients with visceral dominant metastases (42 vs. 23 %;
P = 0.022), whereas the higher ORR for nab-paclitaxel in
patients with a short DFI (43 vs. 33 %; P = NS) was not
statistically significant. In CA024, a significantly higher
ORR for nab-paclitaxel 150 mg/m2 versus docetaxel was
observed in patients with visceral dominant metastases
(76 vs. 37 %; P \ 0.001). No significant differences in
ORR were observed in patients with a short DFI. Although
progression-free survival (PFS) and overall survival
showed trends similar to ORR, statistical significance was
only achieved for comparisons of PFS in patients with
visceral dominant metastases in CA024 (13.1 months for
nab-paclitaxel 150 mg/m2 vs. 7.8 months for docetaxel
[P = 0.019] and 7.5 months for nab-paclitaxel 100 mg/m2
[P = 0.010]). Safety results were similar to previous
reports of the ITT populations. nab-Paclitaxel demon-
strated similar efficacy in patients with poor prognostic
factors as in the ITT populations of these two trials. In each
trial, ORR was significantly higher for nab-paclitaxel
versus the comparator taxane among patients with visceral
dominant metastases.
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Introduction
Breast cancer has the highest incidence and second-highest
mortality rate of any cancer in women worldwide [1]. Only
lung cancer kills more women each year [1]. Although
breast cancer mortality has declined over the last two
decades [1, 2], approximately 30 % of women initially
diagnosed with an earlier stage of breast cancer will
develop metastatic disease, which remains essentially
incurable [3]. Therefore, treatments that provide clinical
benefit among these patients will continue to be sought.
Although the 5-year survival rate for patients diagnosed
with metastatic breast cancer (MBC) remains less than
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25 % [2], a number of factors predict poor survival,
including previous adjuvant chemotherapy, estrogen
receptor (ER) and human epidermal growth factor receptor
2 (HER2) status, short disease-free interval (DFI), the
number of metastatic lesions, site(s) of recurrence, and
visceral involvement [4–8].
Taxanes have proven to be one of the most active
classes of antitumor agents for MBC [3]. The evolution of
taxane approval for the treatment of MBC began with
paclitaxel in 1994, continued with docetaxel (Taxotere) in
1996, and most recently included nanoparticle albumin-
bound (nab-) paclitaxel (Abraxane) in 2005 [9]. The
activity of taxane monotherapy in patients with MBC who
have one or more poor prognostic factors has been well
documented, both in the first-line setting and in the context
of progressive/resistant disease [10–12].
nab-Paclitaxel was developed to take advantage of the
antitumor activity of paclitaxel while decreasing or elimi-
nating the toxicities typically associated with the solvent
(Cremophor EL) used to administer the most common
formulation of paclitaxel [13–15]. Results from the phase
III trial (N = 454) that led to the approval of nab-paclitaxel
demonstrated that nab-paclitaxel at 260 mg/m2 every
3 weeks (q3w) achieved a higher overall response rate
(ORR; 33 vs. 19 %; P = 0.001) and a longer time to tumor
progression (23.0 vs. 16.9 weeks; HR 0.75; P = 0.006)
compared with paclitaxel at 175 mg/m2 q3w in patients
with MBC who were treated in the Cfirst-line setting [14].
Among patients who received Csecond-line treatment for
MBC, the median overall survival (OS) for nab-paclitaxel
was significantly greater than that of paclitaxel (56.4 vs.
46.7 weeks; P = 0.024). Grade 4 neutropenia was less
frequent among patients who received nab-paclitaxel (9 vs.
22 %; P \ 0.001), but grade 3 sensory neuropathy occur-
red at a higher rate (10 vs. 2 %; P \ 0.001).
In order to evaluate the activity of nab-paclitaxel in a
first-line MBC population and explore whether a weekly
schedule might offer favorable clinical outcomes relative to
the approved q3w schedule, a randomized phase II trial
(N = 300) was conducted [16]. Patients received one of the
following treatments: nab-paclitaxel 300 mg/m2 q3w,
100 mg/m2 the first 3 of 4 weeks (qw 3/4), or 150 mg/m2 qw
3/4 or docetaxel at 100 mg/m2 q3w. This study demon-
strated superior efficacy and safety of weekly nab-paclitaxel
compared with docetaxel. nab-Paclitaxel 150 mg/m2 qw 3/4
had the highest investigator-assessed ORR (74 vs. 46 %
for nab-paclitaxel 300 mg/m2 q3w [P = 0.002], 63 % for
nab-paclitaxel 100 mg/m2 qw 3/4 [P not statistically
significant, NS], and 39 % for docetaxel [P \ 0.001]).
nab-Paclitaxel 150 mg/m2 qw 3/4 also demonstrated the
longest investigator-assessed progression-free survival
(PFS; 14.6 vs. 10.9 months for nab-paclitaxel 300 mg/m2
q3w [P = NS], 7.5 months for nab-paclitaxel 100 mg/m2
qw 3/4 [P = 0.001], and 7.8 months for docetaxel
[P = 0.012]). Patients who received nab-paclitaxel at
150 mg/m2 qw 3/4 also had the longest median OS (overall
P = 0.047): 33.8 months vs. 27.7, 22.2, and 26.6 months in
patients who received nab-paclitaxel 300 mg/m2 q3w,
100 mg/m2 qw 3/4, and docetaxel, respectively [17]. The
100 mg/m2 nab-paclitaxel arm exhibited the best safety
profile with the lowest rates of grade C3 neutropenia (25 vs.
43–45 % in the other nab-paclitaxel arms and 92 % in the
docetaxel arm), sensory neuropathy (8 vs. 14–17 % in the
other nab-paclitaxel arms and 12 % in the docetaxel arm),
and fatigue (0 vs. 3–5 % in the other nab-paclitaxel arms
and 19 % in the docetaxel arm).
The objective of this analysis was to examine the efficacy
and safety of nab-paclitaxel versus paclitaxel and docetaxel
in patients with poor prognostic factors. As such, we per-
formed a post hoc analysis of patients who received first-line
treatment in the two randomized trials described above to
determine whether the efficacy and safety of nab-paclitaxel




The patient populations for the two trials were analyzed
separately due to differences in treatment and patient eli-
gibility. In both trials, patients C18 years old with patho-
logically confirmed MBC, Eastern Cooperative Oncology
Group (ECOG) performance status B2, and adequate
hematologic, hepatic, and renal function were included. For
the phase III CA012 trial, patients who had received
docetaxel or paclitaxel in the adjuvant setting were per-
mitted if C1 year had passed since completion of that
therapy [14]. Patients in the phase II CA024 study had not
received prior chemotherapy for metastatic disease, but
patients who had received chemotherapy in the neoadju-
vant or adjuvant setting were permitted if C1 year had
passed since completion of that therapy [16]. Patients with
preexisting sensory neuropathy of grade C1 were excluded
from CA012, whereas patients in CA024 were permitted to
enroll with grade B1 sensory neuropathy.
Study design and assessments
This is a retrospective analysis of patients from the
randomized, multicenter phase III trial (CA012) and a ran-
domized, multicenter phase II trial (CA024). For detailed
information on the trial designs, see Gradishar et al. [14, 16],
respectively. Although patients enrolled in CA012 could
have received chemotherapy for metastatic disease if the
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treatment did not contain solvent-based paclitaxel or doce-
taxel, this analysis only includes those patients who had not
received prior chemotherapy for metastatic disease. Trial
CA024 included only patients who received first-line treat-
ment. Within each of the six treatment arms among the two
studies, patients were subdivided into the following sub-
groups for this analysis: patients with visceral dominant
metastases and patients with a short DFI (B2 years).
The primary efficacy endpoint for both studies was
ORR, defined as complete response ? partial response.
Responses were assessed by the trial investigators using
Response Evaluation Criteria in Solid Tumors [18]. Other
efficacy endpoints in this analysis included median OS and
PFS. The safety endpoints included in this analysis were
treatment-related adverse events, including sensory neu-
ropathy, neutropenia, and fatigue. Hematologic toxicity
was reported on the basis of central laboratory data.
In the CA012 trial, patients received either nab-paclit-
axel at 260 mg/m2 q3w or paclitaxel at 175 mg/m2 q3w. In
the CA024 trial, patients received docetaxel at 100 mg/m2
q3w or nab-paclitaxel at 300 mg/m2 q3w, 100 mg/m2 qw
3/4, or 150 mg/m2 qw 3/4.
Statistical methods
The statistical analyses for the two trials were carried out
separately as it was not appropriate to combine patient
populations. Descriptive statistics were used to calculate
the ORRs and 95 % binomial confidence intervals. Median
OS and PFS values were calculated using Kaplan–Meier
methods. For CA012, the median PFS represented the time
from first dose to disease progression or death, and the
median OS represented the time from first dose to death.
For CA024, the median PFS represented the time from
patient randomization to disease progression or death, and
the median OS represented the time from patient random-
ization to death. Tumor shrinkage was calculated as the
percent change in size from baseline of the target lesion to
the smallest post-baseline measurement.
Results
Patients
The CA012 trial included 97 and 89 patients who received
first-line therapy in the nab-paclitaxel and paclitaxel
treatment arms, respectively. The numbers of patients per
treatment arm in the intent-to-treat (ITT) population of
CA024 ranged from 74 to 76. Baseline characteristics




In the CA012 trial, ORR results for each poor prognostic
factor subset were similar to the results from the general
ITT population (Fig. 1). The ORR was higher with nab-
paclitaxel versus paclitaxel in patients with visceral dom-
inant disease (42 vs. 23 %; P = 0.022) and short DFI (43
vs. 33 %; P = 0.417). Similarly, ORR values among
patients with poor prognostic factors in trial CA024 also
corresponded to the trends in the ITT population. In both
subsets, patients who received nab-paclitaxel on a qw 3/4
schedule exhibited higher ORRs compared with patients
who received docetaxel (Fig. 1). Although comparisons
within the short DFI subgroups failed to reach statistical
significance, comparisons among patients with visceral
dominant lesions did demonstrate significant differences
for ORR.
The mean maximum percent tumor shrinkage was also
calculated for all patients in this analysis. Waterfall plots of
tumor shrinkage for study CA012 are shown in Fig. 2 as a
patient-by-patient overlay of treatment groups from the
least tumor shrinkage to the most tumor shrinkage. Among
patients with visceral dominant metastases (Fig. 2A), the
mean maximum percent tumor shrinkage was 37.4 % in the
nab-paclitaxel arm versus 19.9 % in the paclitaxel arm
(P = 0.006). The difference in mean percent tumor
shrinkage among patients with a short DFI was not statis-
tically significant (Fig. 2B; 39.9 % for nab-paclitaxel vs.
25.4 % for paclitaxel; P = 0.096). The tumor shrinkage
data for study CA024 are shown in Supplemental Figs. 1
(visceral dominant metastases) and 2 (short DFI). For
patients with visceral dominant metastases, patients who
received nab-paclitaxel 300 mg/m2 q3w, 100 mg/m2 qw
3/4, and 150 mg/m2 qw 3/4 had mean maximum percent
tumor shrinkages of 35.5 %, 47.5 %, and 57.1 %, respec-
tively, versus 37.0 % for the docetaxel group. For patients
with a short DFI, patients who received nab-paclitaxel
300 mg/m2 q3w, 100 mg/m2 qw 3/4, and 150 mg/m2 qw
3/4 had mean maximum percent tumor shrinkages of
36.2 %, 48.1 %, and 56.1 %, respectively, versus 32.6 %
for the docetaxel group. None of the differences for study
CA024 were statistically significant.
Progression-free survival
In trial CA012, PFS values in both poor prognostic factor
subsets favored the nab-paclitaxel arm, although the dif-
ferences were not statistically significant (Table 2). Trial
CA024 also showed PFS trends among the patient subsets
that reflected those of the ITT population. Comparisons of
PFS in patients with visceral dominant metastases revealed
Breast Cancer Res Treat (2013) 138:829–837 831
123
statistically significant differences between nab-paclitaxel
150 mg/m2 qw 3/4 and docetaxel and between both qw 3/4
nab-paclitaxel treatment groups. In both prognostic factor
subsets, the nab-paclitaxel 150 mg/m2 qw 3/4 treatment
arm showed the longest PFS values (13.1 and 14.1 months
in the visceral dominant metastases and short DFI groups,
respectively).
Overall survival
In this subset analysis, no comparisons for median OS
reached statistical significance. In CA012, median OS was
numerically higher with nab-paclitaxel versus paclitaxel in
each of the subgroups (Table 3). Trial CA024 once again
demonstrated similar trends in each patient subgroup
compared with the ITT population. In patients with visceral
dominant lesions, OS was numerically highest in patients
who received nab-paclitaxel 150 mg/m2 qw 3/4, while in
patients with a short DFI, the OS was numerically highest
with nab-paclitaxel 100 mg/m2 qw 3/4.
Treatment exposure
As the administered dose of nab-paclitaxel in the CA012
trial was higher than that of paclitaxel, patients in that
treatment arm received a higher median cumulative dose
(1,560 mg/m2 for patients in both subgroups who received
nab-paclitaxel vs. 962.5 mg/m2 for patients in both sub-
groups who received paclitaxel) and a higher dose intensity
(86.6 mg/m2/week for patients with visceral dominant
metastases who received nab-paclitaxel and 85.3 mg/m2/
week for patients with a short DFI who received nab-
paclitaxel vs. 58.3 mg/m2/week for patients in both sub-
groups who received paclitaxel). Treatment delays and
dose reductions occurred at similar frequencies between
the two treatment arms across both prognostic subgroups.
Patients in the nab-paclitaxel arm received a median of 6
cycles of treatment in both groups versus 5.5 for patients in
the paclitaxel arm in both groups. The average dose
intensities among the two patient subgroups for the nab-
paclitaxel arms in trial CA024 ranged from 99.5 to 100 mg/
m2/week in the 300 mg/m2 arm, 73.7–75 mg/m2/week in
the 100 mg/m2 arm, and 98.7–103.1 mg/m2/week in the
150 mg/m2 arm. The median number of cycles received
was highest for the nab-paclitaxel 150 mg/m2 qw 3/4 arm
among patients with visceral dominant metastases (9 vs. 8
in the other arms), but among patients with a short DFI,
patients in the nab-paclitaxel 100 mg/m2 qw 3/4 arm
received the highest number of cycles (8 vs. 6–7 in the
other arms). Among the poor prognostic factor subgroups





















nab-P 260 mg/m2 q3w 74 52.2 70 (95) 72.4 68 (92) 6 (8) 52 (70)
P 175 mg/m2 q3w 64 53.0 60 (94) 71.5 63 (98) 1 (2) 45 (70)
CA024
nab-P 300 mg/m2 q3w 61 51.6 59 (97) 73.2 55 (90) 6 (10) 39 (64)
nab-P 100 mg/m2 qw 3/4 60 55.6 59 (98) 71.8 56 (93) 4 (7) 50 (83)
nab-P 150 mg/m2 qw 3/4 59 53.8 59 (100) 76.1 55 (93) 4 (7) 45 (76)
Doc 100 mg/m2 q3w 67 56.2 67 (100) 75.9 65 (97) 2 (3) 57 (85)
Short DFI
CA012
nab-P 260 mg/m2 q3w 42 50.8 42 (100) 72.4 39 (93) 3 (7) 31 (74)
P 175 mg/m2 q3w 30 52.3 30 (100) 70.0 30 (100) 0 21 (70)
CA024
nab-P 300 mg/m2 q3w 20 49.5 20 (100) 73.2 18 (90) 2 (10) 13 (65)
nab-P 100 mg/m2 qw 3/4 21 51.4 21 (100) 75.7 21 (100) 0 17 (81)
nab-P 150 mg/m2 qw 3/4 14 52.2 14 (100) 80.1 12 (86) 2 (14) 9 (64)
Doc 100 mg/m2 q3w 19 51.5 19 (100) 84.5 19 (100) 0 14 (74)
DFI disease-free interval, nab-P nab-paclitaxel, Doc docetaxel, ECOG PS Eastern Cooperative Oncology Group performance status, P paclit-
axel, q3w every 3 weeks, qw 3/4 the first 3 of 4 weeks
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in trial CA024, the highest rate of dose reductions took
place in the nab-paclitaxel 150 mg/m2 qw 3/4 arm (44 and
50 % among patients with visceral dominant metastases
and a short DFI, respectively), followed by docetaxel (30
and 26 %, respectively), and the two other nab-paclitaxel
arms, which showed similar rates of dose reductions among
the patient subgroups (14–18 %).
Safety
Tables 4 and 5 show the all-grade adverse events and the
grade C3 adverse events, respectively, for the patients with
poor prognostic factors in both trials. Safety results across the
patient subgroups for trial CA012 were similar to the ITT
population: grade 3/4 neutropenia was more frequent for
paclitaxel in the poor prognostic factor subgroups, whereas
sensory neuropathy and fatigue were both more frequent for
nab-paclitaxel (Table 5). In trial CA024, rates of grade 3/4
adverse events in the patient subgroups very closely matched
those of the ITT populations (Table 5). Accordingly, patients
in each treatment arm had similar frequencies of specific
adverse events for each poor prognostic factor subgroup. In
the two subgroups, the rates of grade 3/4 neutropenia and
fatigue were highest for the docetaxel group and lowest in the
nab-paclitaxel 100 mg/m2 qw 3/4 group (no cases of grade
3/4 fatigue were reported in either qw 3/4 nab-paclitaxel
arm). The nab-paclitaxel 100 mg/m2 qw 3/4 dose also
produced the lowest rate of grade C3 sensory neuropathy in
each prognostic factor subgroup.
Discussion
The results of this analysis indicate that the treatment
benefits observed for nab-paclitaxel versus paclitaxel in the
ITT populations of a randomized phase III trial and versus
docetaxel in a randomized phase II trial also apply to
patients with poor prognostic factors. In general, ORR, OS,
PFS, safety, and treatment exposure were similar for each
treatment arm among patients with visceral dominant
metastases and patients with a short DFI. For trial CA012,
the difference in ORR reached statistical significance in the
subset of patients with visceral dominant metastases. In
CA024, both qw 3/4 nab-paclitaxel arms exhibited higher
ORRs versus docetaxel in the visceral dominant metastasis
subgroup. The differences in ORR and the trends in median
PFS and OS suggest that nab-paclitaxel provides clinical
benefit to patients with virulent MBC who received first-
line treatment.
This retrospective analysis was limited by two key
factors. First, the patient subsets examined in this retro-
spective study were not large enough to allow statistical
significance for some of the differences in efficacy out-
































 For the short DFI subgroup, no statistically significant differences were found between treatment arms within either trial. 
P values from study CA012 were calculated by Cochran-Mantel-Haenszel (CMH) test. 
P values from study CA024 were calculated by CMH test, stratified by study site.
Fig. 1 Overall response rate.
DFI disease-free interval, Doc
docetaxel, nab-P nab-paclitaxel,
ORR overall response rate,
P paclitaxel, q3w every
3 weeks, qw 3/4 the first 3 of
4 weeks
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absolute terms relative to the ITT populations of the two
clinical trials. In addition, certain patient data, such as ER
status, progesterone receptor status, and HER2 status were
not collected in these trials.
A separate retrospective analysis examined patient-
s C65 years old in these two studies [19]. It should be
noted that for CA024, the numbers of patients C65 years
old among the different treatment arms ranged from only 9
to 19. Nevertheless, that report reflected a common theme
with the results of this study: the efficacy benefits of nab-
paclitaxel relative to the other taxanes in these two trials
were consistent among patient subgroups. Indeed, the ORR
values for patients C65 years old in trial CA012 were
27 % for nab-paclitaxel versus 19 % for paclitaxel, and
median PFS values were 5.6 and 3.5 months, respectively.
Among patients C65 years old in CA024, ORR values
were 22 % in the nab-paclitaxel 300 mg/m2 q3w group and
60–64 % in the qw 3/4 treatment groups versus 32 % in the
docetaxel group. PFS values for all three nab-paclitaxel
arms were longer than those for the docetaxel arm
(9.2–18.9 vs. 8.5 months).
A recent presentation at the 2012 annual meeting of the
American Society of Clinical Oncology gave results of a
large phase III trial conducted by the Cancer and Leukemia
Group B (CALGB) comparing three regimens for the first-
line treatment of MBC: nab-paclitaxel ± bevacizumab
(n = 271), paclitaxel ± bevacizumab (n = 283), and ix-
abepilone ± bevacizumab (n = 245) [20]. Although the
trial protocol was amended to make bevacizumab use
optional, 98 % of patients received it. The dose selected for
Fig. 2 Mean maximum percent
tumor shrinkage in study
CA012. DFI disease-free
interval, q3w every 3 weeks
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nab-paclitaxel in this trial was 150 mg/m2 qw 3/4, marking
the first time that a dose this high has been used in a phase
III trial. Preliminary results from the trial suggest that the
survival outcomes were similar with nab-paclitaxel and
paclitaxel when given with bevacizumab; however, higher
rates of dose reduction and discontinuation in the nab-
paclitaxel arm suggest suboptimal delivery of the 150 mg/
m2 dose of nab-paclitaxel when given in combination with
bevacizumab. The preliminary findings of the CALGB
study do not address a comparison of nab-paclitaxel versus
paclitaxel outside of the combination with bevacizumab in
patients with virulent MBC. Thus, further research may be
required to determine the optimal weekly dose of nab-
paclitaxel.
The results of this analysis of patients with visceral
dominant metastases and a short DFI suggest that nab-
paclitaxel exhibits substantial clinical activity in patients
with virulent MBC. The efficacy of nab-paclitaxel versus
paclitaxel and docetaxel in these two trials suggests that a
phase III trial prospectively examining the effect of nab-






Doc docetaxel, HR hazard ratio,
nab-P nab-paclitaxel, NS not
statistically significant,
P paclitaxel, PFS progression-
free survival, q3w every
3 weeks, qw 3/4 the first 3 of
4 weeks
a P values from log-rank test
b For study CA024, only
significant results shown
Trial/treatment PFS (months), median
Visceral dominant metastasis Short DFI
n PFS (95 % CI) n PFS (95 % CI)
Study CA012
nab-P 260 mg/m2 q3w 74 5.6 (4.3–7.2) 42 5.0 (3.6–6.6)
P 175 mg/m2 q3w 64 3.8 (3.5–5.1) 30 3.5 (2.7–5.1)
HR (95 % CI) 0.717 (0.483–1.063) 0.729 (0.437–1.215)
P valuesa 0.094 0.220
Study CA024
nab-P 300 mg/m2 q3w (A) 61 10.9 (7.6–13.8) 20 7.4 (2.4–10.3)
nab-P 100 mg/m2 qw 3/4 (B) 60 7.5 (7.2–9.3) 21 7.3 (7.2–9.3)
nab-P 150 mg/m2 qw 3/4 (C) 59 13.1 (9.8–17.7) 14 14.1 (6.2–18.4)
Doc 100 mg/m2 q3w (D) 67 7.8 (5.8–10.3) 19 5.5 (3.1–10.3)
HRb C versus D: 0.600 All NS
B versus C: 1.731
P valuesa,b Overall: 0.049 All NS
C versus D: 0.019
B versus C: 0.010
Table 3 Overall survival
CI confidence interval,
DFI disease-free interval,
Doc docetaxel, HR hazard ratio,
nab-P nab-paclitaxel, NS not
statistically significant,
OS overall survival,
P paclitaxel, q3w every
3 weeks, qw 3/4 the first 3 of
4 weeks
a Values from log-rank test
Trial/treatment OS (months), median
Visceral dominant metastasis Short DFI
n OS (95 % CI) n OS (95 % CI)
Study CA012
nab-P 260 mg/m2 q3w 74 15.1 (11.5–19.0) 42 14.6 (10.7–18.1)
P 175 mg/m2 q3w 64 14.2 (11.8–22.5) 30 11.7 (8.8–18.3)
HR (95 % CI) 1.251 (0.841–1.859) 0.942 (0.567–1.565)
P valuesa 0.268 0.819
Study CA024
nab-P 300 mg/m2 q3w 61 27.7 (20.5–38.9) 20 16.6 (12.1–22.0)
nab-P 100 mg/m2 qw 3/4 60 19.6 (14.5–26.0) 21 19.1 (13.2–28.1)
nab-P 150 mg/m2 qw 3/4 59 32.1 (23.9–40.6) 14 18.6 (10.6–[37.5)
Doc 100 mg/m2 q3w 67 21.4 (18.0–31.3) 19 14.4 (11.4–18.0)
P values All NS All NS
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Table 4 All-grade toxicity
DFI disease-free interval, Doc
docetaxel, nab-P nab-paclitaxel,
P paclitaxel, q3w every
3 weeks, qw 3/4 the first 3 of
4 weeks
a 60 Patients evaluable for
neutropenia
b 65 Patients evaluable for
neutropenia
c 19 Patients evaluable for
neutropenia
Adverse events, n (%) n Neutropenia Sensory neuropathy Fatigue
Visceral dominant metastasis
CA012
nab-P 260 mg/m2 q3w 74 56 (76) 51 (69) 37 (50)
P 175 mg/m2 q3w 64 51 (80) 37 (58) 31 (48)
CA024
nab-P 300 mg/m2 q3w 61a 55 (92) 49 (80) 23 (38)
nab-P 100 mg/m2 qw 3/4 60 48 (80) 38 (63) 20 (33)
nab-P 150 mg/m2 qw 3/4 59 53 (90) 49 (83) 28 (47)
Doc 100 mg/m2 q3w 67b 65 (100) 44 (66) 39 (58)
Short DFI
CA012
nab-P 260 mg/m2 q3w 42 30 (71) 30 (71) 20 (48)
P 175 mg/m2 q3w 30 28 (93) 16 (53) 15 (50)
CA024
nab-P 300 mg/m2 q3w 20c 17 (89) 14 (70) 9 (45)
nab-P 100 mg/m2 qw 3/4 21 17 (81) 15 (71) 6 (29)
nab-P 150 mg/m2 qw 3/4 14 14 (100) 11 (79) 4 (29)
Doc 100 mg/m2 q3w 19 19 (100) 15 (79) 9 (47)
Table 5 Grade C3 toxicity
DFI disease-free interval, Doc
docetaxel, nab-P nab-paclitaxel,
P paclitaxel, q3w every
3 weeks, qw 3/4 the first 3 of
4 weeks
a 60 Patients evaluable for
neutropenia
b 65 Patients evaluable for
neutropenia
c 19 Patients evaluable for
neutropenia
Adverse events, n (%) n Neutropenia Sensory neuropathy Fatigue
Visceral dominant metastasis
CA012
nab-P 260 mg/m2 q3w 74 29 (39) 9 (12) 11 (15)
P 175 mg/m2 q3w 64 37 (58) 3 (5) 1 (2)
CA024
nab-P 300 mg/m2 q3w 61a 27 (45) 11 (18) 3 (5)
nab-P 100 mg/m2 qw 3/4 60 15 (25) 5 (8) 0
nab-P 150 mg/m2 qw 3/4 59 25 (42) 13 (22) 3 (5)
Doc 100 mg/m2 q3w 67b 61 (94) 8 (12) 13 (19)
Short DFI
CA012
nab-P 260 mg/m2 q3w 42 10 (24) 4 (10) 5 (12)
P 175 mg/m2 q3w 30 20 (67) 0 1 (3)
CA024
nab-P 300 mg/m2 q3w 20c 8 (42) 4 (20) 1 (5)
nab-P 100 mg/m2 qw 3/4 21 3 (14) 1 (5) 0
nab-P 150 mg/m2 qw 3/4 14 6 (43) 3 (21) 0
Doc 100 mg/m2 q3w 19 19 (100) 2 (11) 4 (21)
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